Senseera Information

Senseera’s novel chromatin-based liquid biopsy (Sadeh et al., Nature Biotechnology, 2021) is a patented, first-in-class biomarker discovery platform. GEM (Genomic Expression Maps) Biomarkers convert a simple blood draw into high-resolution, quantitative, cell-specific gene expression and regulatory data from cell-free DNA—reflecting the activity of tissues and organs across the body. Surpassing traditional cfDNA genomics and methylation techniques, GEM Biomarkers provide a transformative data layer enabling applications such as biomarker discovery, tissue-agnostic MRD detection, therapy response monitoring, dose optimization, disease subtyping, and more. With a growing database of over 20,000 annotated disease samples and a cohort of more than 2,000 healthy individuals, Senseera partners with leading pharmaceutical and biotech companies to deliver mechanistic insights with unmatched sensitivity and specificity—accelerating drug development and advancing precision medicine worldwide.